ADASUVE 2-dose Thorough QT/QTc Study

NCT01854710 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

UNKNOWN

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: ADASUVE 10 mg 2 doses 2 hours apart
DRUG: Inhaled Placebo
DRUG: Oral moxifloxacin 400 mg
DRUG: Oral placebo

Sponsor

Alexza Pharmaceuticals, Inc.